Precigen
Precigen is a Maryland-based clinical stage biopharmaceutical company that develops gene and cellular therapies for the treatment of immuno-oncology and autoimmune disorders.
Business Model:
Revenue: $138.8M
Employees: 201-500
Industries / Tags:
Detailed Precigen Information
Geographic Data
Address: 20358 Seneca Meadows Parkway
City: Germantown
State: MD
Zip: 20876
Country: US
Financial Info
Stage:
post ipo equity
Raised Last:
$129M
Raised Total:$526M
Social
Metrics
4,151,259Website Global Rank
2,725Website Monthly Traffic
Twitter Followers
Description
Precigen is a Maryland-based clinical stage biopharmaceutical company that develops gene and cellular therapies for the treatment of immuno-oncology and autoimmune disorders.
Contact Phone:
+13015569900
Contact Email:
Precigen went public on 8/13/2013 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
8/13/2013
Ticker Symbol:
PGEN
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2014 | Histogenics | Post-IPO Equity | 0 |
| 12/2014 | Histogenics | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 1/2021 | Post-IPO Equity | $129.4M | 1/2023 | Post-IPO Equity | $75M | 2/2020 | Post-IPO Equity | $35M | 5/2005 | Series B | 1 | $500k |
Third Security Third Security |
9/2015 | Post-IPO Equity | $21.6M | 3/2010 | Series D | $17.4M | 5/2011 | Series E | $0 |
Randal J. Kirk NewVa Capital Partners Third Security Randal J. Kirk NewVa Capital Partners Third Security |
12/2020 | Post-IPO Equity | $13M | 1/2023 | Post-IPO Equity | $75M | 2/2016 | Post-IPO Equity | $4.3M | 1/2020 | Post-IPO Equity | $35M | 3/2006 | Venture Round | $0 |
NewVa Capital Partners NewVa Capital Partners NewVa Capital Partners NewVa Capital Partners |
1/2015 | Post-IPO Equity | $57.5M | 7/2009 | Series C | $10M | 5/2007 | Series C | 1 | $25M |
Third Security Third Security Third Security Third Security |
5/2013 | Series F | $0 |
Randal J. Kirk Third Security Randal J. Kirk Third Security |
5/2013 | Series F | 2 | $150M |
Randal J. Kirk Third Security Randal J. Kirk Third Security |
5/2011 | Series E | 3 | $100M |
Randal J. Kirk NewVa Capital Partners Third Security Randal J. Kirk NewVa Capital Partners Third Security |
3/2006 | Venture Round | 1 | $1M |
NewVa Capital Partners NewVa Capital Partners NewVa Capital Partners NewVa Capital Partners |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 1/2017 | GenVec | |
| 2/2016 | EnviroFlight | |
| 8/2015 | Oxitec | |
| 2/2015 | ActoGeniX | |
| 12/2013 | Medistem | |
| 10/2011 | Immunologix | |
| 2/2011 | Agarigen, Inc |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
